Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX vs Gemcitabine in Metastatic Pancreatic Adenocarcinoma Non-fit for FOLFIRINOX
NCT04167007Phase 3Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2020
- Primary completion
- Jul 2025
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, folinic acid, fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by Assistance publique - Hôpitaux de Paris. Status: unknown.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04167007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167007.